Investment Rating - The report maintains a "Buy" rating for several companies including WuXi Biologics, Tigermed, and others, indicating a positive outlook for the sector [3][12][17]. Core Insights - The report emphasizes the importance of focusing on Q1 performance expectations and actively seizing thematic opportunities, particularly in areas like brain-computer interfaces, surgical robots, and AI healthcare [6][15]. - The surgical robot market in China is projected to grow rapidly, with a potential market size exceeding 100 billion yuan by 2033, driven by policy support and increasing clinical demand [10][30]. - The report highlights a strategic focus on the raw material drug sector, which is expected to see a turnaround due to rising prices and the introduction of new business lines such as small nucleic acids and ADCs [7][15]. Summary by Sections Market Performance - In February 2026, the pharmaceutical sector experienced a slight decline of 0.2%, underperforming compared to the Shanghai Composite Index, which rose by 0.1% [6][11]. - The report notes that various sub-sectors within pharmaceuticals, such as traditional Chinese medicine and medical devices, showed positive performance, with increases of 1.49% and 0.93% respectively [6][15]. Surgical Robots - The surgical robot market is on track to reach a scale of 1020.19 billion yuan by 2033, with a compound annual growth rate (CAGR) of 34.3% from 2024 to 2033 [10][23]. - The report discusses the establishment of a unified pricing framework for surgical robots, which is expected to enhance procurement willingness among hospitals [30][31]. Thematic Opportunities - The report suggests focusing on thematic opportunities in brain-computer interfaces, surgical robots, and AI healthcare, particularly as catalysts are expected to materialize soon [6][15]. - Companies such as Innovent Biologics and others are highlighted as key players in the biotech and biopharma sectors, with potential for significant growth [9][16]. Raw Material Drugs - The raw material drug sector is identified as being at a turning point, with expectations of price improvements following several years of decline [7][15]. - Companies like Pro Pharma and others are recommended for their strong business fundamentals and potential for growth in this sector [7][15].

Core Insights - The company is advancing multiple clinical research programs, including Nectin-4 ADC (9MW2821) and B7-H3 ADC (7MW3711), targeting various cancers with promising clinical data and development strategies [1][2][5]. Group 1: Nectin-4 ADC (9MW2821) - Nectin-4 ADC (9MW2821) utilizes a next-generation conjugation technology, MMAE toxin, and DAR4 design, currently in clinical research for urothelial carcinoma, cervical cancer, triple-negative breast cancer, and esophageal cancer [1][4]. - Over 1,900 patients have been enrolled in clinical trials, with several indications progressing ahead of global competitors [1][4]. - Three pivotal Phase III trials are ongoing, with interim analyses planned for 2026, potentially leading to a new drug application meeting with CDE [1][4]. Group 2: B7-H3 ADC (7MW3711) - B7-H3 ADC (7MW3711) has completed Phase II trials, with data presented at the 2025 ESMO conference showing an objective response rate (ORR) of 42.9% for esophageal cancer and 50.0% for small cell lung cancer at a dose of 4.0 mg/kg [2][5]. - The drug demonstrates good tolerability and anti-tumor activity, with a disease control rate (DCR) of 100% for esophageal cancer and 90.0% for small cell lung cancer [2][5]. - The company is pursuing differentiated development strategies, including trials combining 7MW3711 with PD-1/VEGF dual antibodies and platinum-based chemotherapy [6]. Group 3: Small RNA and TCE Platforms - The company has established a small RNA platform focusing on chronic diseases, with the lead candidate 2MW7141 targeting lipid disorders and cardiovascular events, expected to submit IND applications in the US and China this year [3][7]. - The TCE platform features modified CD3 antibodies and secondary signal-activating antibodies, enhancing tumor targeting and reducing off-target effects [8][9]. - 6MW5311, a TCE targeting CD3 and LILRB4, is aimed at treating relapsed/refractory acute myeloid leukemia and is expected to submit IND applications in mid-2026 [9]. Group 4: IL-11 Monoclonal Antibody (9MW3811) - IL-11 monoclonal antibody (9MW3811) is in Phase II trials for pathological scars, with the first patient dosed in December 2025, marking it as the first IL-11 targeted drug for this indication [10]. Group 5: Hong Kong Stock Issuance - The company has submitted an application for H-share issuance on the Hong Kong Stock Exchange and has received a notice for overseas issuance, with the approval process progressing smoothly [11].

Group 1 - The core point of the article is that Maiwei Bio reported a significant increase in total operating revenue for the year 2025, amounting to 662.52 million yuan, which represents a year-on-year growth of 231.62% [2] - The net profit attributable to the parent company for the same period was reported as -970.18 million yuan, indicating a loss [2]

Core Viewpoint - Maiwei Biotech reported significant revenue growth for 2025, with total revenue reaching 663 million yuan, a year-on-year increase of 231.62%. However, the company still recorded a net loss of 970 million yuan, which is an improvement from the previous year's loss of 1.044 billion yuan [1]. Revenue Performance - The company's total revenue for the reporting period was 663 million yuan, marking a substantial increase compared to the previous year [1]. - The revenue growth was primarily driven by significant income recognized from licensing agreements with Qilu Pharmaceutical Co., Ltd. and DISC MEDICINE, INC., as well as a notable increase in drug sales revenue compared to the same period last year [1]. Net Loss Analysis - The net loss attributable to the parent company's shareholders was 970 million yuan, which is a reduction from the net loss of 1.044 billion yuan in the same period last year [1].

Financial Performance - Total revenue for 2025 reached RMB 66,251.56 million, a significant increase of 231.62% compared to RMB 19,978.16 million in the previous year[3] - The company's net profit attributable to shareholders was RMB -97,017.55 million, showing a decrease from RMB -104,391.92 million year-on-year[3] - The basic earnings per share were RMB -2.43, slightly improved from RMB -2.61 in the previous year[3] - The weighted average return on net assets dropped by 48.77 percentage points to -99.05% compared to -50.28% in the previous year[3] Assets and Equity - The total assets at the end of the reporting period were RMB 456,784.79 million, reflecting a 6.84% increase from RMB 427,550.89 million at the beginning of the period[3] - The equity attributable to shareholders decreased by 77.78% to RMB 34,866.59 million from RMB 156,887.74 million[3] Revenue Drivers - The increase in total revenue was primarily due to significant income from licensing agreements with Qilu Pharmaceutical Co., Ltd. and DISC MEDICINE, INC., along with increased drug sales[5] R&D and Investment - The company maintained high levels of R&D investment as multiple innovative drugs are in critical trial phases, impacting overall financial performance[6] - The decrease in equity and net asset value was attributed to substantial investments in new drug development and increased operating costs due to commercialization efforts[6] Investment Risks - There are no significant uncertainties affecting the accuracy of the financial report, but investors are advised to be cautious regarding investment risks[7]

Investment Rating - The report assigns an "Outperform" rating for the company, indicating a positive outlook for its future performance [4]. Core Insights - The company is positioned as an innovative biopharmaceutical enterprise with a comprehensive industry chain layout and a clear direction for innovation, focusing on unmet clinical needs in oncology and aging-related diseases [2][9]. - The company has established a dual-driven innovation model through self-developed technologies and business development (BD) partnerships, enhancing its pipeline and market presence [2][4]. - The company is actively expanding its product offerings and entering new markets, with a focus on both domestic and international growth strategies [4][21]. Summary by Relevant Sections Company Overview - The company was founded in 2017 and went public on the Shanghai Stock Exchange in 2022, with plans for a Hong Kong listing to support its international expansion [9]. - The management team is experienced, with a stable shareholding structure, ensuring strategic decisions align with the company's core needs [11][13]. Research and Development - The company has multiple R&D platforms, including ADC, TCE, MyoDock™, and small nucleic acids, which work synergistically to achieve innovation and differentiation [22][23]. - The pipeline is rich, focusing on oncology for immediate returns while also developing anti-aging therapies for long-term growth [28]. Business Development Strategy - The company employs a diversified approach to business development, combining internal capabilities with external partnerships to maximize pipeline value [4][19]. - Collaborations with various partners, including local and global firms, are aimed at enhancing product commercialization and expanding market reach [4][21]. Financial Projections and Valuation - Revenue projections for 2025 to 2027 are estimated at 6.74 billion, 11.63 billion, and 12.73 billion RMB, respectively, indicating significant growth potential [4]. - The current market valuation is considered undervalued based on the company's projected cash flow and product pipeline [4]. Product Pipeline Highlights - The core product, Nectin-4 ADC (9MW2821), is in advanced clinical trials for multiple indications, including urothelial carcinoma and cervical cancer, with potential peak sales estimated at 1.988 billion RMB [31][33]. - The company is also developing innovative therapies for Alzheimer's disease and chronic obstructive pulmonary disease, showcasing its commitment to addressing critical health challenges [2][28].

Investment Rating - The report assigns an "Buy" rating for the company, marking the first coverage of its stock [4]. Core Insights - The company, Maiwei Biopharmaceuticals, is positioned as an innovative biopharmaceutical enterprise with a comprehensive industry chain layout and clear innovation direction, focusing on unmet clinical needs in oncology and aging-related diseases [2][9]. - The company has established a dual-driven innovation model through self-research and business development (BD), leveraging its unique technology platforms and differentiated product pipelines to create value [2][4]. - The revenue forecast for the company shows significant growth, with projected revenues of 674 million RMB in 2025, 1.163 billion RMB in 2026, and 1.273 billion RMB in 2027, reflecting a compound annual growth rate (CAGR) of 238% from 2024 to 2025 [4]. Summary by Sections Company Overview - Maiwei Biopharmaceuticals has transitioned from a "generic-innovative" model to a "global innovation" approach, with plans for a Hong Kong IPO to support its sustainable development and international expansion [9]. - The company has a stable shareholding structure and an experienced management team, with a focus on drug development and commercialization [11][13]. Research and Development - The company has multiple R&D platforms, including ADC, TCE, MyoDock™, and small nucleic acids, which work in synergy to achieve rapid innovation and differentiation [22][23]. - The pipeline is rich, with a focus on oncology products for immediate returns and anti-aging products for long-term growth [28]. Business Development Strategy - Maiwei has adopted a diversified and integrated approach to business development, forming partnerships to enhance product value and cash flow [4][19]. - The company is actively expanding its biosimilar drug business, which is crucial for cash flow, while also pursuing global market opportunities [4][19]. Financial Projections and Valuation - The company is expected to see a significant improvement in cash flow due to the anticipated success of its BD initiatives and the commercialization of its biosimilars [4]. - The estimated equity valuation of the company is 26.845 billion RMB, indicating that the current market valuation is undervalued [4].

Core Viewpoint - The article discusses the current funding logic in the market, highlighting the significant movements of public funds in the technology sector, particularly in the semiconductor and biopharmaceutical industries, as they adjust their portfolios based on performance and valuation metrics [3][8]. Group 1: Public Fund Movements - Public funds have shown a notable shift in their holdings, particularly in the STAR Market, with the STAR 50 Index rising by 12.1% this year [3][4]. - The total market capitalization of STAR Market companies reached 10.4 trillion yuan, with the technology sector dominating, accounting for 62.1% of the total market cap [5][6]. - The semiconductor industry remains the core focus for fund allocation, with 12 companies in the sector having a market capitalization exceeding 10 billion yuan [9][11]. Group 2: Semiconductor Sector Insights - The market's pricing anchor for the semiconductor sector has shifted from "valuation expansion" to "performance realization," emphasizing the importance of actual earnings [13][14]. - Key drivers for future growth in the semiconductor sector include strong order backlogs, profit growth through acquisitions and expansions, and sustained price increases in advanced processes [13][14]. - Public funds have significantly increased their holdings in semiconductor materials, chip design, and equipment, with companies like ShenGong Co. seeing an 11% increase in fund holdings [15][21]. Group 3: Biopharmaceutical Sector Insights - The biopharmaceutical sector is a critical area for public funds, with major holdings in companies like BeiGene and United Imaging Healthcare, although the sector has faced a reduction in holdings for several key companies [24][26]. - The article notes that innovative drug companies are currently under pressure, with significant reductions in holdings observed in companies like BaiLi TianHeng and RongChang Biopharma [26][28]. - Despite the challenges, companies with strong earnings potential and innovative drug pipelines are still attracting interest from public funds, indicating a selective investment approach [35][40].

北京植德（上海）律师事务所 北京植德（上海）律师事务所 关于迈威（上海）生物科技股份有限公司 关于迈威（上海）生物科技股份有限公司 2026 年第一次临时股东会的 法律意见书 植德沪（会）字[2026]0004 号 二〇二六年二月 上海市徐汇区虹桥路 183 号徐家汇中心三期 A 座办公楼 27 层（THREE itc） 邮编：200030 27th Floor Tower A, THREE itc, No.183 Hongqiao Road, Xuhui District, Shanghai 200030 P.R.C 电话(Tel)：021-52533500 传真(Fax)：021-52533599 www.meritsandtree.com 2026 年第一次临时股东会的 法律意见书 植德沪（会）字[2026]0004 号 致：迈威（上海）生物科技股份有限公司（贵公司） 北京植德（上海）律师事务所（以下简称"本所"）接受贵公司的委托，指 派律师出席并见证贵公司 2026 年第一次临时股东会（以下简称"本次会议"）。 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、 ...

证券代码：688062 证券简称：迈威生物 公告编号：2026-006 迈威（上海）生物科技股份有限公司 2026年第一次临时股东会决议公告 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 129 | | --- | --- | | 普通股股东人数 | 129 | | 2、出席会议的股东所持有的表决权数量 | 205,575,336 | | 普通股股东所持有表决权数量 | 205,575,336 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 51.4452 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 51.4452 | （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 会议采取现场投票和网络投票相结合的表决方式，表决程序符合《中华人民 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席 ...